Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate

• Status: Suspended
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd. in patients of both sexes, patients with plaque psoriasis grade mild to moderate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Azidus Brasil
• Treatments: Mometasone Furoate; Salicylates; Salicylic Acid

Criteria

Inclusion Criteria:

• Adults of both sexes, regardless of color or social class;

• Age 18 or older, with good mental health;

• Patients with plaque psoriasis of mild to moderate;

• Patients who agree to participate and sign the Informed Consent and

• Clarified (appendix);

• Patients who agree to return for follow-up visits.

Exclusion Criteria:

• Patients who are making use of biologics, steroids or steroidal anti-inflammatory and non-steroidal or who made use of these topical medications until 15 days ago 30 days ago or when occurred in oral administration;

• Patients who are exposing themselves to the sun 15 days before the study began or during the course of the same.

• Patients who are making use of acetaminophen;

• Patients who do not agree to the terms described in the informed consent Informed Consent;

• Patients who also have psoriatic plaques of skin disorders caused by fungi or bacteria and who are making use of antimycotics or antibiotics;

• Lions and other types of skin damage than those psoriasis;

• Pregnant and nursing women;

• Patients using oral anticoagulants.